In addition to the high percentage of uncontrolled patients in our study, these estimates revealed that the current use of insulin therapy in T2DM patients is still insufficient; thus, improving clinical practice to be more adherent to global guidelines and improving insulin accessibility are required. The gene discussed is INS; the disease is type 2 diabetes mellitus.